Joshua T. Brumm - Nov 15, 2023 Form 4 Insider Report for Dyne Therapeutics, Inc. (DYN)

Role
Chief Executive Officer and President, Director
Signature
/s/ Richard Scalzo, Attorney-in-Fact
Stock symbol
DYN
Transactions as of
Nov 15, 2023
Transactions value $
$0
Form type
4
Date filed
11/16/2023, 04:29 PM
Previous filing
Sep 20, 2023
Next filing
Dec 12, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DYN Common Stock Award $0 +359K +153.58% $0.00 593K Nov 15, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DYN Stock Option (right to buy) Award $0 +140K $0.00 140K Nov 15, 2023 Common Stock 140K $10.88 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of shares of Common Stock issuable under 358,877 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on February 15, 2024.
F2 Includes 569,116 unvested RSUs.
F3 This option was granted on November 15, 2023. The shares underlying the option are scheduled to vest over four years in equal monthly installments through November 15, 2027.

Remarks:

Chief Executive Officer and President